IL298767A - ALK2 inhibitors for the treatment of anemia - Google Patents
ALK2 inhibitors for the treatment of anemiaInfo
- Publication number
- IL298767A IL298767A IL298767A IL29876722A IL298767A IL 298767 A IL298767 A IL 298767A IL 298767 A IL298767 A IL 298767A IL 29876722 A IL29876722 A IL 29876722A IL 298767 A IL298767 A IL 298767A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- formula
- mds
- administered
- anemia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063039742P | 2020-06-16 | 2020-06-16 | |
| US202063056761P | 2020-07-27 | 2020-07-27 | |
| US202163152516P | 2021-02-23 | 2021-02-23 | |
| PCT/US2021/037377 WO2021257532A1 (en) | 2020-06-16 | 2021-06-15 | Alk2 inhibitors for the treatment of anemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL298767A true IL298767A (en) | 2023-02-01 |
Family
ID=76845323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL298767A IL298767A (en) | 2020-06-16 | 2021-06-15 | ALK2 inhibitors for the treatment of anemia |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11723899B2 (https=) |
| EP (1) | EP4164641A1 (https=) |
| JP (1) | JP2023530316A (https=) |
| KR (1) | KR20230025444A (https=) |
| CN (1) | CN115968289B (https=) |
| AU (1) | AU2021292484A1 (https=) |
| CA (1) | CA3187767A1 (https=) |
| CL (2) | CL2022003511A1 (https=) |
| IL (1) | IL298767A (https=) |
| MX (1) | MX2022015900A (https=) |
| PH (1) | PH12022553501A1 (https=) |
| TW (1) | TW202214239A (https=) |
| WO (1) | WO2021257532A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118955715A (zh) | 2018-10-23 | 2024-11-15 | 科乐斯疗法公司 | Alk2抗体及其使用方法 |
| CN115038443A (zh) | 2019-11-22 | 2022-09-09 | 因西特公司 | 包含alk2抑制剂和jak2抑制剂的组合疗法 |
| US12508262B2 (en) | 2020-04-30 | 2025-12-30 | Keros Therapeutics, Inc. | Methods of using ALK2 inhibitors |
| JP2023530316A (ja) | 2020-06-16 | 2023-07-14 | インサイト・コーポレイション | 貧血の治療のためのａｌｋ２阻害剤 |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| WO2022240948A1 (en) * | 2021-05-11 | 2022-11-17 | Keros Therapeutics, Inc. | Methods of using alk2 and alk3 antibodies |
| CN116478145B (zh) * | 2022-04-13 | 2024-02-02 | 杭州邦顺制药有限公司 | Alk2激酶抑制剂 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5077290A (en) | 1990-10-11 | 1991-12-31 | Merck & Co., Inc. | Morpholine derivatives compositions and use |
| TW530054B (en) | 1997-09-24 | 2003-05-01 | Duphar Int Res | New piperazine and piperidine compounds |
| SE0102439D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| EP1501514B1 (en) | 2002-05-03 | 2012-12-19 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| US7015227B2 (en) | 2002-06-21 | 2006-03-21 | Cgi Pharmaceuticals, Inc. | Certain amino-substituted monocycles as kinase modulators |
| US20040067985A1 (en) | 2002-10-04 | 2004-04-08 | Fortuna Haviv | Method of inhibiting angiogenesis |
| SE0203753D0 (sv) | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| EP1623216A2 (en) | 2003-04-11 | 2006-02-08 | SGX Pharmaceuticals, Inc. | Compound libraries and methods for drug discovery |
| CA2567935C (en) | 2004-05-27 | 2009-10-27 | Pfizer Limited | Aminopyridine derivatives as selective dopamine d3 agonists |
| SA05260265A (ar) | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
| AU2006234627C1 (en) | 2005-04-08 | 2009-11-26 | Eisai R & D Management Co., Ltd. | Therapeutic agent for dyskinesia |
| WO2007011760A2 (en) | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
| AR059036A1 (es) | 2006-01-17 | 2008-03-12 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
| CA2658362A1 (en) | 2006-06-29 | 2008-01-03 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors |
| MX2010013876A (es) | 2008-06-20 | 2011-03-04 | Metabolex Inc | Agonistas de arilo grpr119 y sus usos . |
| WO2012088438A1 (en) | 2010-12-22 | 2012-06-28 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
| WO2012161877A1 (en) | 2011-05-23 | 2012-11-29 | Merck Patent Gmbh | Pyridine-and pyrazine derivatives |
| EP2753605B1 (en) | 2011-09-09 | 2019-03-27 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
| KR102092988B1 (ko) | 2012-09-28 | 2020-03-25 | 벤더르빌트 유니버시티 | 선택성 bmp 저해제로써 융합된 헤테로 고리 화합물들 |
| WO2014138088A1 (en) | 2013-03-04 | 2014-09-12 | The Brigham And Women's Hospital, Inc. | Bmp inhibitors and methods of use thereof |
| MX394360B (es) | 2013-03-14 | 2025-03-24 | Sumitomo Pharma Oncology Inc | Inhibidores de jak2 y alk2 y metodos para su uso. |
| BR112016008632A8 (pt) | 2013-10-21 | 2020-03-17 | Merck Patent Gmbh | compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica |
| BR112017015273A2 (pt) | 2015-01-20 | 2018-01-09 | Merial Inc. | compostos e composições antihelmínticos e método de utilizações dos mesmos |
| ES2799300T3 (es) | 2015-08-31 | 2020-12-16 | Dong A Socio Holdings Co Ltd | Compuestos heteroarilo y su uso como fármacos terapéuticos |
| US10710980B2 (en) * | 2016-07-20 | 2020-07-14 | Novartis Ag | Aminopyridine derivatives and their use as selective ALK-2 inhibitors |
| WO2018106820A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| CN114761013A (zh) | 2019-09-27 | 2022-07-15 | 迪斯克医药公司 | 治疗骨髓纤维化和相关病症的方法 |
| US20220372136A1 (en) | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating anemia of chronic disease |
| CN115038443A (zh) * | 2019-11-22 | 2022-09-09 | 因西特公司 | 包含alk2抑制剂和jak2抑制剂的组合疗法 |
| JP2023530316A (ja) | 2020-06-16 | 2023-07-14 | インサイト・コーポレイション | 貧血の治療のためのａｌｋ２阻害剤 |
-
2021
- 2021-06-15 JP JP2022577319A patent/JP2023530316A/ja active Pending
- 2021-06-15 TW TW110121744A patent/TW202214239A/zh unknown
- 2021-06-15 CA CA3187767A patent/CA3187767A1/en active Pending
- 2021-06-15 PH PH1/2022/553501A patent/PH12022553501A1/en unknown
- 2021-06-15 IL IL298767A patent/IL298767A/en unknown
- 2021-06-15 MX MX2022015900A patent/MX2022015900A/es unknown
- 2021-06-15 US US17/348,102 patent/US11723899B2/en active Active
- 2021-06-15 CN CN202180042461.3A patent/CN115968289B/zh active Active
- 2021-06-15 WO PCT/US2021/037377 patent/WO2021257532A1/en not_active Ceased
- 2021-06-15 EP EP21739843.7A patent/EP4164641A1/en active Pending
- 2021-06-15 AU AU2021292484A patent/AU2021292484A1/en active Pending
- 2021-06-15 KR KR1020237001508A patent/KR20230025444A/ko active Pending
-
2022
- 2022-12-09 CL CL2022003511A patent/CL2022003511A1/es unknown
-
2023
- 2023-06-28 US US18/343,267 patent/US12383541B2/en active Active
- 2023-06-30 CL CL2023001952A patent/CL2023001952A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12022553501A1 (en) | 2024-04-22 |
| CN115968289A (zh) | 2023-04-14 |
| US20230338352A1 (en) | 2023-10-26 |
| US20210393605A1 (en) | 2021-12-23 |
| CN115968289B (zh) | 2025-09-30 |
| AU2021292484A1 (en) | 2023-01-19 |
| US12383541B2 (en) | 2025-08-12 |
| TW202214239A (zh) | 2022-04-16 |
| JP2023530316A (ja) | 2023-07-14 |
| EP4164641A1 (en) | 2023-04-19 |
| WO2021257532A1 (en) | 2021-12-23 |
| CA3187767A1 (en) | 2021-12-23 |
| CL2023001952A1 (es) | 2023-12-15 |
| KR20230025444A (ko) | 2023-02-21 |
| CL2022003511A1 (es) | 2023-06-02 |
| US11723899B2 (en) | 2023-08-15 |
| MX2022015900A (es) | 2023-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12383541B2 (en) | ALK2 inhibitors for the treatment of anemia | |
| US11738026B2 (en) | Combination therapy comprising an ALK2 inhibitor and a JAK2 inhibitor | |
| KR20230028484A (ko) | 암의 치료를 위한 병용 요법 | |
| PH12015500246B1 (en) | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor | |
| CN102421429A (zh) | 癌症治疗用选择性ep4受体拮抗物质 | |
| US20240207257A1 (en) | Combination therapy comprising a pkc inhibitor and a mek inhibitor | |
| WO2018158225A1 (en) | Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof | |
| US20240374600A1 (en) | Methods and compositions for treating cancer | |
| EA049111B1 (ru) | Ингибиторы alk2 для лечения анемии | |
| EA049147B1 (ru) | Комбинированный лекарственный препарат, содержащий ингибитор alk2 и ингибитор jak2 | |
| US20240335440A1 (en) | Combination therapy comprising a pkc inhibitor and a c-met inhibitor | |
| WO2025111214A1 (en) | [(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3- carbonyl)amino]acetic acid (roxadustat) for the treatment of anemia in subjects with myelodysplastic syndrome (mds) | |
| CA3227813A1 (en) | Pharmaceutical composition for treating solid tumors | |
| JP2025542349A (ja) | 比較的低リスクの骨髄異形成症候群を治療する方法 |